*Sponsored
Krypton Street Initiates Coverage On Actuate Therapeutics (Nasdaq: ACTU) Starting Today—Wednesday, August 6, 2025
Here's What We Can Tell You Right Now…
(ACTU) Receives Coverage From Two Analysts With The Average Target Suggesting Over 180% Upside Potential
(ACTU) Has Less Than 6Mn Shares—Which Could Lead To The
Potential For Heightened Volatility And Big Swings
(ACTU) Recently Secured Inclusion In Both The Russell 3000®
And Russell 2000® Indexes
Pull Up (ACTU) This Morning—While It's Still Quiet…
August 6, 2025 Coverage Initiated | See Why (ACTU) Just Hit Our Radar This Morning Dear Reader, This morning brought a major development for (ACTU) as it unveiled a new clinical collaboration that unites its lead program, elraglusib, with a PD‑1 inhibitor from a $15B biopharma leader and the research power of one of the nation's top cancer centers. The Phase 1b trial will evaluate this multi‑agent approach as a potential frontline therapy for advanced pancreatic cancer — a disease with few effective options. Building on prior results showing meaningful survival gains, this new study opens the door to exploring synergistic immune‑modulating strategies designed to improve both efficacy and durability of response. See full story here. If you missed my report from just a few minutes, keep reading to quickly get up to speed on (ACTU) why we're so excited to be bringing this to you today. As breakthroughs in cancer therapeutics accelerate, a clinical‑stage biopharmaceutical team is gaining recognition for its targeted approach to some of the toughest and most persistent forms of the disease. By focusing on key molecular pathways, they're working to open doors where traditional treatments often reach their limits. Recent progress includes trial data showing survival gains in advanced, hard‑to‑treat cases — alongside fresh recognition through inclusion in both the Russell 3000® and Russell 2000® Indexes. Add to that a float under 6Mn shares — and two independent analyst targets that average over 180% upside potential — and this situation becomes hard to ignore. Today, that setup puts one name at the top of our watchlist:
Actuate Therapeutics, Inc. (Nasdaq: ACTU)
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead experimental treatment, elraglusib, is designed to block processes in cancer cells that help tumors grow and make them harder to treat with standard therapies like chemotherapy. Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. And based on these 5 potential catalysts, (Nasdaq: ACTU) has taken over the top spot on my watchlist this week. Check these out:
#1. A low float could lead to heightened volatility potential. #2. Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas. #3. Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial. #4. Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes. #5. MarketBeat is reporting two separate, strong analyst targets. But more on those in a second...
Key Company Highlights - Important Details Surrounding (Nasdaq: ACTU)
(1.) Moving forward with elraglusib, a promising treatment candidate being tested in several Phase 2 trials for advanced cancers, using a unique approach that targets cancer in multiple ways. (2.) Clinical responses (CRs/PRs) and Disease Control observed across cancer histologies Extended survival and increased responses are observed in mPDAC and relapsed/refractory Ewing sarcoma. Preliminary evidence of clinical benefit has also been observed in patients with metastatic melanoma and relapsed/refractory colorectal and lung cancer. (3.) Oral version of elraglusib successfully evaluated in Healthy Volunteer Phase 1. Phase 1 dose escalation study planned in advanced cancer patients. (4.) Broad composition of matter IP protection and development incentives. Orphan Drug Designations for pancreatic and other cancer types; Fast Track Designation for pancreatic cancer. Strategic Pipeline Growth for GSK-3β Associated Diseases
Take A Look At The Sources Found Here: ACTU Presentation. ==== These (Nasdaq: ACTU) Potential Breakout Catalysts Require Full Attention!
#1. A low float could lead to heightened volatility potential.
According to info from the Yahoo website, (ACTU) has a fairly low float. The website reports this profile to have roughly 5.98Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears in the midway part of 2025, could this low float potential help provide a breakout spark?
#2. Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas.
"Refractory and resistant EWS is one of the most aggressive and underserved cancers affecting children and young adults with very low survival rates," said Dr. Andrew Mazar, Actuate's Scientific Co-founder and Chief Operating Officer. "To observe complete responses in this setting is highly unexpected, and these exceptional early results position elraglusib as a potential first-in-class therapy option in an indication where no approved targeted therapies currently exist."
"We are highly encouraged by the responses observed in refractory and resistant EWS, a disease where treatment options are extremely limited beyond frontline chemotherapy," said Daniel Schmitt, President & Chief Executive Officer of Actuate. "With these promising clinical signals in hand, we are advancing our development plans focused on EWS by pursuing a Phase 2 trial and plan to meet with regulators to discuss potential registration path in this indication."
#3. Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial.
"We are highly encouraged by the significant clinical benefit provided by elraglusib demonstrated in this study," said Daniel Schmitt, President & Chief Executive Officer of Actuate. "Patients who received at least one cycle – or 4 weeks – of elraglusib showed a rapid and meaningful survival benefit, including a near doubling of the 1-year overall survival and 43% reduction in the risk of death compared to control. Separately, in the subgroup of patients with liver metastases, a population with historically poor prognosis, we observed a more than 2.5-fold improvement in 1-year OS with a 38% reduction in risk of death. These results underscore the potential of elraglusib to generate rapid and durable benefit in high-risk patients, which could be highly impactful in future development and commercial pathways."
#4. Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes.
"Inclusion in the Russell 3000® and 2000® Indexes represents a significant milestone for Actuate and reflects the company's strong momentum since our IPO last year," said Daniel Schmitt, President & Chief Executive Officer of Actuate. "It comes on the heels of very positive topline Phase 2 data in mPDAC, which showed that the trial met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival (mOS) of 10.1 months compared to 7.2 months (p = 0.01), with a 37% reduction in the risk of death (HR = 0.63), reinforcing the therapeutic potential of our lead candidate, elraglusib. This recognition not only elevates our visibility within the in-vest-ment community but also validates our platform and strategic direction. As we advanced the development of elraglusib, we believe this is a pivotal moment that further positions Actuate for long-term growth and value creation."
#5. MarketBeat is reporting two separate, strong analyst targets.
Check these out:
Based on the two analyst targets of $21 and $20, (ACTU) could have approximately 180% upside potential from its recent levels. ==== Recap - 5 Potential Catalysts Put (Nasdaq: ACTU) On Radar
#1. MarketBeat is reporting two separate, strong analyst targets.
#2. A low float could lead to heightened volatility potential. #3. Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas. #4. Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial. #5. Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes. ==== We have officially initiated coverage on Actuate Therapeutics, Inc. (Nasdaq: ACTU), starting today—Wednesday, August 6, 2025. Keep an eye out for further updates as (ACTU) advances this newly launched trial and explores how its lead program could reshape the treatment landscape for advanced pancreatic cancer. Also–watch for my next update—it could be hitting at any moment. Sincerely, Alex Ramsay
Co-Founder / Managing Editor Krypton Street Newsletter
| 
